Clinical significance of aminopeptidase N in non-small cell lung cancer

Clinical Cancer Research

Volumn 12, Issue 13, 2006, Pages 3971-3978

  Tokuhara, Takahiro ^a,b   Hattori, Noboru ^a   Ishida, Hisao ^a   Hirai, Tatsuya ^a   Higashiyama, Masahiko ^c   Kodama, Ken ^c   Miyake, Masayuki ^a  

^a Kitano Hospital   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MH8 11; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER PATIENT; CANCER STAGING; CELL MOTILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; EXTRACELLULAR MATRIX; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD13; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE;

EID: 33746080895     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0338     Document Type: Article

References (37)

1. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
2. Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-8.
3. Hart IR, Saini A. Biology of tumour metastasis. Lancet 1992;339:1453-7.
4. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
5. Hashida H, Takabayashi A, Kanai M, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002;122:376-86.
6. Bhagwat SV, Lahdenranta J, Giordano R, et al. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 2001;97:652-9.
7. Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 1993;82:1052-70.
8. Saiki I, Fujii H, Yoneda J, et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 1993;54:137-43.
9. Fujii H, Nakajima M, Saiki I, et al. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin Exp Metastasis 1995;13:337-44.
10. Yoneda J, Saiki I, Fujii H, et al. Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin). Clin Exp Metastasis 1992;10:49-59.
11. Ino K, Goto S, Okamoto T, et al. Expression of aminopeptidase N on human choriocarcinoma cells and cell growth suppression by the inhibition of aminopeptidase N activity. Jpn J Cancer Res 1994;85:927-33.
12. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722-7.
13. Ikeda N, Nakajima Y, Tokuhara T, et al. Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res 2003;9:1503-8.
14. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
15. Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T. Molecular structure of the human cytoplasmic β-actin gene: interspecies homology of sequences in the introns. Proc Natl Acad Sci U S A 1985;82:6133-7.
16. 5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin Cancer Res 2000;6:96-101.
17. Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
18. McCarty KS, Jr., Szabo E, Flowers JL, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986;46:4244-8s.
19. Tandon AK, Clark GM, Chamness GC, et al. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990;322:297-302.
20. Matsuyama K, Chiba Y, Sasaki M, et al. Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. Ann Thorac Surg 1998;65:1405-9.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
23. Look AT, Ashmun RA, Shapiro LH, et al. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 1989;83:1299-307.
24. Olsen J, Kokholm K, Troelsen JT, et al. An enhancer with cell-type dependent activity is located between the myeloid and epithelial aminopeptidase N (CD13) promoters. Biochem J 1997;322:899-908.
25. Lerche C, Vogel LK, Shapiro LH, et al. Human aminopeptidase N is encoded by 20 exons. Mamm Genome 1996;7:712-3.
26. Shapiro LH, Ashmun RA, Roberts WM, et al. Separate promoters control transcription of the human aminopeptidase N gene in myeloid and intestinal epithelial cells. J Biol Chem 1991;266:1199-2007.
27. Menrad A, Speicher D, Wacker J, et al. Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res 1993;53:1450-5.
28. Kehlen A, Langner J, Riemann D. Transforming growth factor-β increases the expression of aminopeptidase N/CD13 mRNA and protein in monocytes and monocytic cell lines. Adv Exp Med Biol 2004;77:49-56.
29. Ishii K, Usui S, Sugimura Y, et al. Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 2001;92:49-54.
30. Ichinose Y, Genka K, Koike T, et al. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J Natl Cancer Inst 2003;95:605-10.
31. Yasumitsu T, Ohshima S, Nakano N, et al. Bestatin in resected lung cancer. A randomized clinical trial. Acta Oncol 1990;29:827-31.
32. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
33. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
34. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small-cell lung cancer (NSCLC). Report of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract 7019]. Proc Am Soc Clin Oncol 2004;22:621.
35. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial-E4599 [abstract LBA4]. J Clin Oncol 2005;23:2S.
36. Lu C, Soria JC, Tang X, et al. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 2004;22:4575-83.
37. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-21.